DEALS: Teva buys CoGenesys for $400M


Teva buys CoGenesys for $400M


DEALS

WHO

WITH

WHAT

SCOOP

Pfizer

Washington University

$25M

Washington University and Pfizer researchers will identify, design and execute projects focused on immuno-inflammatory disorders such as arthritis, asthma and diabetes.

Forest Laboratories

Novexel's

$109.6 million

Forest gains development rights to Novexel's intravenous beta lactamase inhibitor, NXL 104, in combination with Forest's ceftaroline.

Teva

CoGenesys

$400 million

Teva says the buyout will give it a better position to compete in the fledgling biogeneric field.

 

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.